Harnessing The Gut–Metabolic Axis: Synergistic Potential Of Prenylated Flavonoids And Resistant Starch In Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) has emerged as one of the most pressing chronic metabolic disorders of the contemporary era, carrying substantial global morbidity and healthcare burden .^1,2 Pathophysiologically, T2DM is characterized by progressive insulin resistance in peripheral tissues and deteriorating pancreatic β-cell function, resulting in sustained hyperglycemia and impaired glucose homeostasis.³

The rising prevalence of T2DM is driven by interacting factors including excess adiposity, reduced physical activity, calorie-rich dietary patterns, psychosocial stress, and genetic predisposition.⁴ Beyond hyperglycemia, T2DM is accompanied by oxidative stress, chronic low-grade inflammation, dyslipidemia, mitochondrial dysfunction, and vascular endothelial injury —all of which synergistically underlie serious long-term sequelae including cardiovascular events, kidney damage, peripheral neuropathy, retinal deterioration, and hepatic impairment.^1,3,4

Accumulating evidence has established gut microbiota dysbiosis has a significant mechanistic role in T2DM pathogenesis by impairing intestinal barrier integrity, promoting metabolic endotoxemia, and driving chronic inflammation and insulin resistance.^3,4 These observations have highlighted the gut–metabolic axis as an important therapeutic target in diabetes management.^5,6 The detailed pathophysiology is discussed in Section 2.

Current pharmacological therapies—including metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and exogenous insulin—primarily achieve glycemic control through single or limited mechanistic targets.⁷ Prolonged use of these agents, however, is associated with gastrointestinal intolerance, hypoglycemic episodes, body weight changes, progressive attenuation of response, and insufficient modulation of the underlying inflammatory and microbial disturbances.⁷

Given the multifactorial nature of T2DM, there exists a compelling therapeutic imperative for interventions that can simultaneously address hyperglycemia, oxidative stress, inflammation, gut microbial imbalance, and impaired insulin signaling.⁸

In this setting, dietary polyphenols and flavonoids have gained considerable scientific attention for their capacity to restrain carbohydrate-digesting enzymes, enhance insulin signaling pathways, reduce oxidative damage, and dampen inflammatory cascades.^9,10,11 A persistent limitation of many naturally occurring flavonoids is their inadequate aqueous solubility, restricted transmembrane passage, rapid biotransformation, and poor systemic bioavailability, constraining their clinical utility.^12,13 Structural modification through prenylation—the enzymatic addition of dimethylallyl or geranyl moieties—substantially improves lipophilicity, cellular uptake, metabolic stability, and biological efficacy compared to parent compounds.^14,15,16 Emerging evidence also indicates that prenylated polyphenols may support mitochondrial function and skeletal muscle energy metabolism, conferring supplementary metabolic advantages.^17,18

Resistant starch (RS) is a dietary fiber-like non-digestible carbohydrate that bypasses small intestinal digestion and undergoes colonic fermentation by gut microbiota, yielding SCFAs that promote metabolic wellbeing, enhanced insulin responsiveness, and preserve intestinal mucosal integrity.^19,20,21

Converging findings suggest that co-administration of polyphenols with RS may yield additive or synergistic benefits through complementary effects on gut microbial ecosystem, SCFA generation presents a comprehensive assessment of the therapeutic utility, inflammatory pathway regulation, and insulin signaling—providing a multi-target approach uniquely suited to the complex pathophysiology of T2DM.^22,23

This review therefore presents a comprehensive assessment of the therapeutic utility of prenylated flavonoids and RS in T2DM, focusing on enzyme inhibition, gut microbiota modulation, SCFA-mediated metabolic regulation, HDAC inhibition, inflammatory pathway control, and improvement of insulin sensitivity as integrated multi-target natural interventions.

PATHOPHYSIOLOGY OF GUT DYSBIOSIS IN TYPE 2 DIABETES MELLITUS

T2DM is a multifactorial metabolic disorder defined by chronic hyperglycemia arising from progressive insulin resistance and pancreatic β-cell dysfunction. The gut microbiota—comprising approximately 10¹³–10¹⁴ microorganisms—maintains systemic metabolic homeostasis through coordinated regulation of nutrient metabolism, intestinal barrier integrity, immune function, and endocrine signaling.² Gut dysbiosis—a qualitative and quantitative imbalance in microbial communities—has been recognized as an active mechanistic driver of T2DM through perturbations in microbial metabolite profiles, breakdown of mucosal barrier integrity, systemic endotoxin translocation, inflammatory activation, disrupted incretin and bile acid signaling, and eventual β-cell exhaustion.^3,4

Shifts in Gut Microbial Composition and Ecological Diversity

A defining characteristic of T2DM-related dysbiosis is reduced alpha-diversity coupled with systematic compositional shifts, including an elevated Firmicutes-to-Bacteroidetes ratio and depletion of Verrucomicrobia and Actinobacteria populations.²⁴ Beneficial commensals are substantially diminished: Akkermansia muciniphila (which fortifies the mucosal barrier and enhances insulin sensitization), Faecalibacterium prausnitzii (a key anti-inflammatory butyrate producer), Roseburia intestinalis and Eubacterium rectale (colonic butyrate synthesizers), and Bifidobacterium and Lactobacillus spp. (immunomodulators and barrier protectors).^24,25 Concurrently, opportunistic taxa—Escherichia coli, Ruminococcus gnavus, and sulfate-reducing Desulfovibrio spp.—expand, augmenting LPS, BCAA, and trimethylamine (TMA) production while reducing beneficial SCFAs, secondary bile acids, and indole derivatives.^26,27 Notably, hyperglycemia itself reshapes microbial ecology, establishing bidirectional reinforcing feedback loops.

Impaired Intestinal Barrier Function and Increased Permeability

The intestinal barrier comprises a mucus bilayer, polarized epithelial cells joined by tight junction (TJ) complexes—occludin, claudins-1/-3/-4/-5, and zonula occludens-1 (ZO-1)—and the gut-associated lymphoid tissue (GALT).² In dysbiosis, depletion of SCFA-producing commensals reduces butyrate availability, impairing transcriptional upregulation of claudin-1, occludin, and ZO-1 via HDAC inhibition and PPARγ signaling.^28,29 Reduced Akkermansia muciniphila abundance diminishes MUC2 production and mucus layer thickness. Expansion of proteolytic taxa promotes epithelial apoptosis through caspase-3/-9 activation and degrades TJ proteins via microbially derived proteases and hydrogen sulfide. The resulting increase in intestinal permeability permits translocation of luminal antigens and endotoxins, initiating and sustaining systemic inflammatory responses.

Metabolic Endotoxemia, TLR4 Activation, and Chronic Inflammation

Increased intestinal permeability enables systemic translocation of lipopolysaccharide (LPS), a glycolipid constituent of the outer membrane of Gram-negative bacteria.^2,3 Elevated circulating LPS—referred to as metabolic endotoxemia—correlate with fasting insulin levels, insulin resistance indices, and inflammatory markers. LPS complexes with LPS-binding protein (LBP) and activates Toll-like receptor 4 (TLR4) via CD14 on macrophages, adipocytes, and hepatocytes.³ TLR4 engagement triggers the MyD88-dependent cascade (IRAK–TRAF6–IKK–NF-κB) and TRIF-dependent pathway (TBK1–IRF3), both activating MAPK (JNK, p38). NF-κB-driven transcription produces TNF-α, IL-1β, IL-6, and MCP-1, establishing chronic metaflammation. The NLRP3 inflammasome amplifies metabolic tissue injury by processing pro-IL-1β and pro-IL-18 into biologically active forms.⁸

Cellular and Molecular Mechanisms of Insulin Resistance

Under normal metabolic conditions, insulin receptor activation triggers IRS-1/IRS-2 tyrosine phosphorylation, PI3K–PIP₃–PDK1–Akt signaling, and GLUT4 translocation to the plasma membrane. TNF-α and IL-1β disrupt this cascade by activating JNK and IKKβ, which catalyze inhibitory serine phosphorylation of IRS-1 and promote its proteasomal degradation, attenuating PI3K-Akt signaling and impairing glucose uptake in skeletal muscle and adipose tissue.^2,3 Within the liver, JNK and NF-κB activation upregulates gluconeogenic enzymes (PEPCK, G6Pase), augmenting hepatic glucose production. IL-6-induced SOCS3 further dampens insulin responsiveness via JAK-STAT3 signaling.⁵

Short-Chain Fatty Acid Deficiency and Epigenetic Consequences

SCFAs—butyrate, propionate, and acetate—are produced by microbial fermentation of dietary fiber at approximate molar ratios of 60:20:20. They signal through GPR41 (FFAR3) and GPR43 (FFAR2) on enteroendocrine cells and adipocytes to stimulate GLP-1/PYY secretion and suppress lipolysis.¹⁹ Butyrate exerts potent epigenetic effects through class I/II HDAC inhibition, suppressing NF-κB-driven inflammation and inducing Foxp3+ regulatory T cell (Treg) differentiation.^28,29 Metabolically, butyrate activates AMPK and PGC-1α, promoting mitochondrial biogenesis and fatty acid β-oxidation.^30,31 SCFA deficiency in dysbiosis simultaneously increases intestinal permeability, amplifies inflammation, impairs insulin signaling, and disrupts mucosal immune homeostasis.

Dysregulation of Incretin Hormones and Bile Acid Signaling

Incretin hormones—principally GLP-1 and GIP—account for up to 70% of postprandial insulin secretion. SCFA-mediated GPR41/43 activation on intestinal L-cells stimulates GLP-1 and PYY secretion; secondary bile acids further stimulate GLP-1 via TGR5; and indole derivatives from microbial tryptophan catabolism augment L-cell GLP-1 release through the aryl hydrocarbon receptor (AhR).^32,33 In dysbiosis, reduced SCFA production and altered bile acid profiles impair L-cell stimulation, leading to GLP-1 deficiency, accelerated gastric emptying, reduced satiety signaling, and progressive β-cell secretory failure.^31,33 Gut bacteria expressing bile salt hydrolase (BSH) and 7α-dehydroxylase convert primary bile acids into secondary forms (deoxycholic acid, lithocholic acid), activating FXR and TGR5. When dysbiosis shifts the bile acid pool toward conjugated primary forms, hepatic gluconeogenesisis augmented, attenuating GLP-1 secretion, and worsening insulin resistance.³⁴

BCAA Dysmetabolism and TMAO-Mediated Dysfunction

Circulating BCAAs (leucine, isoleucine, valine) represent independent predictors of insulin resistance and T2DM risk. Dysbiotic species such as Prevotella copri and Bacteroides vulgatus augment BCAA biosynthesis while impairing catabolism through suppression of the BCKDH complex. Elevated BCAAs activate mTORC1–S6K1, inducing inhibitory serine phosphorylation of IRS-1 and attenuating PI3K-Akt signaling.^35,36

Trimethylamine N-oxide (TMAO), generated from dietary choline, phosphatidylcholine, and L-carnitine via microbial CutC/D and hepatic FMO3, independently correlates with insulin resistance and T2DM risk. TMAO activates PERK-mediated ER stress, inhibiting Akt phosphorylation and amplifying inflammatory cytokine production. It additionally antagonizes FXR, promoting hepatic steatosis, and drives adipose macrophage M1 polarization.^35,36

Immune Dysregulation, Oxidative Stress, and β-Cell Dysfunction

Gut dysbiosis disrupts the mucosal equilibrium between pro-inflammatory Th17 cells and immunosuppressive regulatory T cells (Tregs), shifting toward a pro-inflammatory state that amplifies intestinal permeability via IL-17A/F-mediated MMP activation and claudin-1 suppression.^2,3 Chronic inflammatory signaling from gut-derived mediators drives pathological ROS generation through NOX2/NOX4 activation and mitochondrial electron transport chain disruption.^4,5 Overwhelming ROS accumulation exceeds the capacity of endogenous antioxidant systems (SOD1/SOD2, catalase, Nrf2-Keap1), oxidatively modifying the insulin receptor and IRS proteins. In skeletal muscle, mitochondrial dysfunction reduces oxidative phosphorylation capacity; in the liver, ROS-mediated PP2A activation augments gluconeogenesis; and in endothelium, superoxide scavenging of nitric oxide impairs insulin-stimulated vasodilation.^2,3,4

Pancreatic β-cells are particularly vulnerable to inflammatory and oxidative insults due to low antioxidant enzyme expression. IL-1β and IFN-γ activate NF-κB within β-cells, inducing iNOS-derived NO overproduction that impairs electron transport, depletes NAD+/ATP, and triggers apoptosis via caspase-3/-8. Sustained ER stress activates the unfolded protein response (UPR) through PERK, IRE1α, and ATF6 branches, ultimately inducing CHOP-driven apoptosis, suppressing key transcription factors (PDX-1, MafA, Nkx6.1), and promoting β-cell dedifferentiation. Concomitant incretin deficiency further removes the GLP-1 trophic and anti-apoptotic signal that normally supports β-cell survival.^4,31

Adipose Tissue Inflammation and the Gut–Brain Axis

Gut-derived LPS, transported by postprandial chylomicrons, activates TLR4 on visceral adipose macrophages, polarizing them toward the M1 phenotype (TNF-α, IL-6, MCP-1 production) and stimulating hormone-sensitive lipase (HSL) and ATGL to drive lipolysis.^2,3 Elevated circulating NEFAs propagate insulin resistance in muscle and liver through TLR4 activation and PKC-mediated IRS-1 serine phosphorylation. NF-κB-mediated suppression of adiponectin removes a key AMPK/PPARα-activating insulin-sensitizing signal, while chronic hyperleptinemia induces central leptin resistance.^2,3,4

The bidirectional gut–brain axis, communicating via the vagus nerve, ENS, systemic microbial metabolites, and immune mediators, represents an additional dimension of dysbiosis-mediated metabolic dysfunction. Approximately 90–95% of peripheral serotonin is synthesized by enterochromaffin cells under microbial regulation; its dysregulation impairs gut motility, nutrient transit, and satiety signaling.^3,4 Inflammatory cytokines and metabolites (LPS, TMAO, kynurenine) can traverse the blood–brain barrier to activate hypothalamic microglia, promoting central insulin and leptin resistance. SCFA-mediated GPR41/43 signaling in hypothalamic and brainstem nuclei, attenuated in dysbiotic states, further disrupts central appetite and energy homeostasis.⁸

Figure1 illustrates the mechanistic connection between gut dysbiosis and insulin resistance in T2DM. In the healthy metabolic state, a balanced dietary intake maintains tight junctions in the intestinal epithelium and supports beneficial bacteria such as Bifidobacteria, Faecalibacterium, and Akkermansia, along with robust SCFA production — particularly butyrate and acetate — that maintains gut barrier integrity. In contrast, an unbalanced diet leads to dysbiosis, characterized by expansion of pathogenic Gram-negative LPS-producing bacteria, reduced SCFA levels, and loosening of tight junctions, resulting in a leaky gut. This allows lipopolysaccharide (LPS) endotoxins to translocate into the bloodstream, where they activate TLR4 receptors on immune cells, triggering the release of inflammatory cytokines such as TNF-α and IL-6. These cytokines activate IKKβ and JNK signalling pathways, which induce serine phosphorylation of IRS-1 — acting as an "OFF switch" — thereby blocking the PI3K/Akt pathway, impairing GLUT-4 translocation, and ultimately reducing glucose uptake in muscle and fat cells, leading to insulin resistance and elevated blood sugar levels.

 

Figure 1; Pathophysiological mechanisms linking gut dysbiosis and showing the  progression of Type 2 diabetes mellitus

 

 

Figure 2; Metabolic and immunomodulatory actions of SCFAs  in Type 2 diabetes mellitus.

SHORT-CHAIN FATTY ACIDS, SKELETAL MUSCLE METABOLISM, AND T2DM

Skeletal muscle constitutes the predominant site of insulin-driven glucose disposal, contributing approximately 80% of total postprandial glucose utilization.⁵² In T2DM, skeletal muscle displays impaired insulin signaling, diminished glucose uptake capacity, mitochondrial operational deficits, and altered energy substrate handling that collectively and substantially amplify whole-body insulin resistance and impair glycemic control.⁵³ Emerging investigations indicate that gut microbiota-derived SCFAs modulate skeletal muscle metabolic function through several interconnected molecular mechanisms.^54,55

Skeletal Muscle Dysfunction in T2DM

Under physiological conditions, insulin stimulates IRS-PI3K-Akt-dependent GLUT4 translocation to the sarcolemmal membrane, facilitating cellular glucose uptake. In T2DM, chronic inflammation, oxidative stress, elevated free fatty acids, and mitochondrial dysfunction impair this pathway.⁵² Progressive muscle atrophy and reduced muscle quality further exacerbate metabolic dysfunction, establishing a deteriorating cycle of worsening insulin resistance and declining glucose utilization capacity.^52,53

Contributions to Skeletal Muscle Metabolic Function

SCFAs—particularly acetate, propionate, and butyrate—confer beneficial effects on skeletal muscle metabolism by enhancing insulin responsiveness, facilitating glucose uptake, and attenuating inflammatory signaling.⁵⁵ SCFAs activate AMPK, increase fatty acid oxidation, and promote metabolic flexibility. Propionate may contribute to skeletal muscle glucose metabolism through gluconeogenic pathways and GPR41/43-mediated signaling. Butyrate-driven AMPK and PGC-1α activation stimulates mitochondrial biogenesis, enhances oxidative phosphorylation, and improves ATP production, addressing the mitochondrial dysfunction characteristic of insulin-resistant skeletal muscle.^17,18,55

Prenylated Flavonoids and Muscle Metabolism

In addition to their antidiabetic and antioxidant activities, prenylated flavonoids may support skeletal muscle function through improvements in mitochondrial activity, reduction of oxidative burden, enhancement of insulin signal transduction, and promotion of myocellular glucose utilization.^15,18 Prenylation may further augment these effects through improved membrane permeability and cellular uptake. Although direct evidence for prenylated flavonoids specifically in muscle metabolism remains limited, their capacity to activate AMPK-PGC-1α signaling and suppress inflammatory pathways represents a mechanistic basis for improved skeletal muscle metabolic health in T2DM.¹⁸

SYNERGISTIC APPROACH: PRENYLATED FLAVONOID–RESISTANT STARCH COMPLEX

The combination of prenylated flavonoids with RS represents a promising multi-target nutraceutical strategy for T2DM management. This synergistic approach integrates the direct antihyperglycemic and antioxidant effects of prenylated flavonoids with the gut-mediated metabolic benefits of RS.^22,23 Relative to individual components used in isolation, flavonoid–RS complexes may offer improved physicochemical stability, enhanced oral bioavailability, controlled-release kinetics, improved colon delivery efficiency, and broader metabolic regulation through simultaneous engagement of multiple T2DM pathological pathways.^56,57

Resistant Starch as a Natural Carrier System

RS can serve as a natural biocompatible carrier for bioactive phytoconstituents by virtue of its biodegradability, non-toxic profile, and fermentation-mediated colonic release properties.^56,58 The compact retrograded structure of RS3, in particular, enables encapsulation or surface association with hydrophobic phytoconstituents such as prenylated flavonoids, protecting them from early degradation in the upper gastrointestinal tract.^47,58 Because RS resists salivary and pancreatic enzyme digestion, associated bioactive compounds can remain protected until reaching the colon where microbial fermentation facilitates their controlled release. This makes RS an attractive platform for colon-targeted nutraceutical delivery.⁵⁹

Molecular Interactions Underlying Complex Formation

Complex formation between prenylated flavonoids and RS occurs primarily through non-covalent molecular interactions. The increased hydrophobicity conferred by prenyl groups facilitates interaction with the starch matrix through several mechanisms^23,60 like; Hydrogen bonding between flavonoid hydroxyl groups and starch polymer hydroxyls, hydrophobic interactions between prenyl groups and amylose helical regions, Van der Waals interactions, Electrostatic interactions and Inclusion complex formation within amylose helical structures

These non-covalent interactions may alter crystallinity, molecular arrangement, and physicochemical properties of the complex. Flavonoid–starch systems may form inclusion complexes (flavonoid entrapped within amylose helices), surface adsorption complexes (binding onto starch granule surfaces), or matrix entrapment systems (physical dispersion within retrograded starch matrices).^60,61

It is important to acknowledge that dedicated experimental investigations into prenylated flavonoid–RS complexes specifically remain scarce. The proposed interactions discussed here are based on established knowledge of flavonoid–starch complexes and the physicochemical properties of prenylated flavonoids. Further targeted experimental work is needed to characterize these assemblies and confirm their in vivo metabolic benefits.²³

Preparation: Solvent Dispersion Method

Among available fabrication techniques, solvent dispersion is regarded as a practical and accessible method for preparing flavonoid–RS complexes. The prenylated flavonoid is dissolved in a compatible organic solvent (e.g., ethanol), while RS is separately dispersed in distilled water. Both phases are combined under continuous mechanical agitation to promote flavonoid–starch molecular interaction, followed by controlled solvent evaporation and drying to produce a stable dry complex. This approach is valued for its operational simplicity, economical material requirements, mild processing conditions, and compatibility with thermosensitive phytoconstituents.⁶²

Dual Mechanism of Antidiabetic Action

The prenylated flavonoid–RS complex may exert antidiabetic activity through complementary direct and indirect mechanisms:

Direct Mechanism: Enzyme Inhibition

Prenylated flavonoids inhibit α-amylase and α-glucosidase, delaying starch digestion and intestinal glucose absorption and thereby reducing postprandial hyperglycemia. Prenylation enhances lipophilicity and interaction with enzyme active sites, potentially improving inhibitory potency compared to native flavonoids.^63,64,65

Indirect Mechanism: SCFA Production and Gut Modulation

RS undergoes microbial fermentation in the colon, yielding SCFAs that enhance insulin sensitivity, suppress systemic inflammation, regulate glucose metabolism, and maintain mitochondrial function in metabolically active tissues.^19,20 Among SCFAs, butyrate plays a particularly important role through HDAC inhibition and transcriptional regulation of genes involved in glucose metabolism and inflammatory signaling.^28,29

Concurrently the RS matrix functions as a prebiotic substrate promoting Akkermansia muciniphila, Bifidobacterium, and butyrate-producing bacteria, while flavonoids may help suppress pathogenic taxa and reduce intra-luminal oxidative stress. This combined ecological and biochemical effect strengthens intestinal barrier integrity, reduces metabolic endotoxemia, and enhances insulin sensitivity.^51,66

CHALLENGES AND LIMITATIONS

Despite the promising therapeutic potential of prenylated flavonoid–RS systems in T2DM, several challenges limit clinical translation. Stability concerns are paramount: flavonoids are susceptible to oxidation, pH variation, light exposure, and enzymatic degradation during processing and gastrointestinal transit.^12,13 Although prenylation and RS complexation may improve stability, maintaining long-term structural integrity and bioactivity remains challenging.^22,23

Lack of standardization represents another significant limitation. Variability in plant source, extraction method, degree of prenylation, RS preparation, and complex formation techniques can substantially affect physicochemical properties and biological activity.^14,38 Differences in amylose content, retrogradation conditions, and interaction efficiency further compromise reproducibility.^22,23

Clinical validation of prenylated flavonoid–RS systems remains insufficient, with the preponderance of existing evidence originating from in vitro experiments, rodent disease models, and computational molecular docking analyses.^46,50,51 Rigorously designed human clinical trials evaluating therapeutic efficacy remain scarce. Substantial interindividual variability in gut microbiota composition further complicates therapeutic outcomes, as SCFA production from RS fermentation is highly dependent on microbial diversity and abundance.⁶⁷ These factors highlight the need for personalized, microbiome-informed nutritional approaches.⁶⁷

Supporting mechanistic evidence for the individual components of this strategy remains fragmented across separate lines of investigation. Microbial biotransformation studies have characterized how gut microorganisms metabolize prenylated flavonoids such as prenylquercetin.⁶⁸ Starch-based nano-microcapsule delivery platforms illustrate complementary encapsulation principles for bioactive compounds.⁶⁹ Gut microbiota–metabolome alterations have been characterized in type 2 diabetic patients with peripheral neuropathy.⁷⁰ Systems-level metabolic modelling has further revealed altered microbial community structure and metabolic autonomy within the diabetic gut microbiome.⁷¹ Starch–isoflavone complexation studies illustrate additional starch–polyphenol interaction principles relevant to complex formation.⁷² Functional-food interventions such as Bombyx batryticatus extract have demonstrated hypoglycemic and gut-microbiota-modulating effects in diabetic rodent models.⁷³ Similarly, other gut-microbiota-targeted functional food ingredients have shown beneficial effects in rodent models of diabetes.⁷⁴ Collectively, these findings support the broader feasibility of microbiota-directed nutraceutical strategies, although none directly evaluate a combined prenylated flavonoid–RS system.

Research specifically investigating prenylated flavonoid–RS complexes is still in early stages, representing an emerging and underexplored area in metabolic disease research.^22,23 Further mechanistic, translational, and clinical studies are required to establish long-term efficacy, safety, bioavailability, and therapeutic relevance in diverse human populations.

FUTURE PERSPECTIVES

The combination of prenylated flavonoids and RS holds considerable potential for development of advanced nutraceuticals and functional foods targeting metabolic disorders. Their complementary mechanisms—enzyme inhibition, antioxidant activity, SCFA production, gut microbiota modulation, and colon-targeted delivery—make them attractive candidates for multi-target T2DM management.

Future research priorities include development of RS-based functional foods, encapsulated delivery systems, and synbiotic formulations optimized for bioavailability and metabolic efficacy. Exploration of underutilized starch sources and novel prenylated polyphenols may further expand the therapeutic scope. Large-scale clinical trials are essential to validate long-term efficacy, safety, and pharmacokinetics in diabetic patients.

Deepening insight into inter-individual gut microbial heterogeneity is anticipated to catalyze personalized nutritional medicine approaches in which dietary regimens are individualized according to the patient's microbial fingerprint, metabolic phenotype, and disease trajectory. Such precision nutrition strategies, combined with emerging omics technologies and microbiome-targeted formulations, may provide improved glycemic control and better management of metabolic complications in T2DM.

CONCLUSION

T2DM is a multifactorial metabolic condition encompassing chronic hyperglycemia, oxidative imbalance, persistent systemic inflammation, insulin resistance, and gut microbial dysbiosis. Conventional therapies primarily target individual metabolic pathways and may inadequately address the complex underlying pathophysiology. In this context, prenylated flavonoids and RS have emerged as promising nutraceutical components with antioxidant, anti-inflammatory, enzyme inhibitory, gut microbiota-modulating, and SCFA-mediated metabolic properties.

The strategic co-application or complex of prenylated flavonoids with RS creates a synergistic multi-target framework capable of improving oral bioavailability, enabling colon-targeted delivery, favorably remodeling gut microbial ecology, amplifying SCFA output, and enhancing whole-body insulin sensitivity. Through both direct enzyme inhibitory effects and indirect gut-mediated metabolic regulation, this combination may simultaneously addresses hyperglycemia, inflammation, insulin resistance, gut dysbiosis, and β-cell dysfunction—multiple pathophysiological axes of T2DM.

However, direct experimental studies investigating prenylated flavonoid–RS complexes remain limited, and current evidence is largely derived from preclinical models. Further mechanistic investigations, formulation studies, and well-designed clinical trials are required to validate efficacy, safety, bioavailability, and long-term therapeutic relevance in human subjects. Overall, simultaneous targeting of metabolic and gut-mediated pathways represents a valuable direction for future multi-target interventions against T2DM.

CONFLICT OF INTEREST

The authors have no conflicts of interest regarding this investigation.

REFERENCES

1. Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment. Biochem Biophys Rep. 2025;42:102037.
2. Kiełbowski K, Plewa P, Zadworny J, Stodolak P, Jędrasiak A, Bakinowska E, Pawlik A. What is the involvement of gut microbiome in the pathophysiology of diabetes? Biomolecules. 2025;15(10):1463.
3. Kant R, Chandra L, Verma V, Nain P, Bello D, Patel S. Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus. World J Methodol. 2022;12(4):246–257.
4. Lau WL, Tran T, Rhee CM, Kalantar-Zadeh K, Vaziri ND. Diabetes and the gut microbiome. Semin Nephrol. 2021;41(2):104–113.
5. Chong S, Lin M, Chong D, Jensen S, Lau NS. A systematic review on gut microbiota in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2024;15:1486793.
6. Donati Zeppa S, Gervasi M, Bartolacci A, Ferrini F, Patti A, Sestili P. Targeting the gut microbiota for prevention and management of type 2 diabetes. Nutrients. 2024;16(22):3951.
7. Tariq HMA, Khan NY, Manzoor H, Kayani MUR. Exploring the impact of type 2 diabetes and glucose-lowering drugs on gut microbiome dynamics. Discov Med. 2025;2:47.
8. Nikolaidis CG, Gyriki D, Stavropoulou E, Karlafti E, Didangelos T, Tsigalou C. Modulating the gut microbiome in type 2 diabetes: nutritional and therapeutic strategies. Nutrients. 2026;18(1):89.
9. Shamsudin NF, Ahmed QU, Mahmood S, Shah SAA, Sarian MN, Khattak MMAK. Flavonoids as antidiabetic and anti-inflammatory agents: a review on structure-activity relationship-based studies and meta-analysis. Int J Mol Sci. 2022;23(20):12605.
10. Li M, Ding L, Cao L, Zhang Z, Li X, Li Z, Xia Q, Yin K, Song S, Wang Z, Du H, Zhao D, Li X, Wang Z. Natural products targeting AMPK signaling pathway therapy, diabetes mellitus and its complications. Front Pharmacol. 2025;16:1534634.
11. Ebrahimi R, Mohammadpour A, Medoro A, Davinelli S, Saso L, Miroliaei M. Exploring the links between polyphenols, Nrf2, and diabetes: A review. Biomed Pharmacother. 2025;186:118020.
12. Kumar Singh A, Cabral C, Kumar R, Ganguly R, Kumar Rana H, Gupta A. Beneficial effects of dietary polyphenols on gut microbiota and strategies to improve delivery efficiency. Nutrients. 2019;11(9):2216.
13. El-Sayed Baiomy RF. Quercetin nanoparticles as a therapeutic approach: pharmacological actions and potential applications in therapy. BioTechnologia. 2024;105(4):377–393.
14. Lv HW, Wang QL, Luo M, Zhu MD, Liang HM, Li WJ. Phytochemistry and pharmacology of natural prenylated flavonoids. Arch Pharm Res. 2023;46(4):207-272.
15. Morante-Carriel J, Nájera H, Samper-Herrero A, Živković S, Martínez-Esteso MJ. Therapeutic Potential of Prenylated Flavonoids of the Fabaceae Family in Medicinal Chemistry: An Updated Review - Int J Mol Sci. 2024;25(23):13036.
16. Mukai R, Fujikura Y, Murota K, Uehara M, Minekawa S, Matsui N. Prenylation enhances quercetin uptake and reduces efflux in Caco-2 cells and enhances tissue accumulation in mice fed long-term. J Nutr. 2013;143(10):1558–1564.
17. Saponaro F, Bertolini A, Baragatti R, Galfo L, Chiellini G, Saba A, D'Urso G. Myokines and microbiota: new perspectives in the endocrine muscle-gut axis. Nutrients. 2024;16(23):4032.
18. Mthembu SXH, Dludla PV, Ziqubu K, Nyambuya TM, Kappo AP, Madoroba E. The potential role of polyphenols in modulating mitochondrial bioenergetics within skeletal muscle: a systematic review of preclinical models. Molecules. 2021;26(9):2791.
19. Tang R, Li L. Modulation of short-chain fatty acids as potential therapy method for type 2 diabetes mellitus. Can J Infect Dis Med Microbiol. 2021;2021:6632266.
20. Facchin S, Bertin L, Bonazzi E, Lorenzon G, De Barba C, Barberio B. Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications. Life. 2024;14(5):559.
21. Li X, Chen R, Wen J, Ji R, Chen X, Cao Y, Yu Y, Zhao C. The mechanisms in the gut microbiota regulation and type 2 diabetes therapeutic activity of resistant starches. Int J Biol Macromol. 2024;274(Part 1):133279.
22. Wu Y, Liu Y, Jia Y, Zhang H, Ren F. Formation and application of starch–polyphenol complexes: influencing factors and rapid screening based on chemometrics. Foods. 2024;13(10):1557.
23. Deng X, Ng WH, Zhou Z, Li C. Current understanding of starch-polyphenol complexes and their potential in vivo metabolism, impact on gut microbiota and treating diabetes. Crit Rev Food Sci Nutr. 2025;1–14.
24. Shaheen N, Khursheed W, Gurung B, Wang S. Akkermansia muciniphila: A key player in gut microbiota-based disease modulation. Microbiol Res. 2025;301:128317.
25. Bednarska NG, Håberg AK. Understanding patterns of the gut microbiome may contribute to the early detection and prevention of type 2 diabetes mellitus: a systematic review. Microorganisms. 2025;13(1):134.
26. Beura S, Kundu P, Das AK, Ghosh A. Genome-scale community modelling elucidates the metabolic interaction in Indian type-2 diabetic gut microbiota. Sci Rep. 2024;14:17259.
27. Morsy Y, Shafie NS, Amer M. Integrative analysis of gut microbiota and metabolic pathways reveals key microbial and metabolomic alterations in diabetes. Sci Rep. 2025;15:30686.
28. Chriett S, Dąbek A, Wojtala M, Vidal H, Balcerczyk A, Pirola L. Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci Rep. 2019;9(1):742.
29. Pedersen SS, Ingerslev LR, Olsen M, Prause M, Billestrup N. Butyrate functions as a histone deacetylase inhibitor to protect pancreatic beta cells from IL-1β-induced dysfunction. FEBS J. 2024;291(3):566–583.
30. Morrison DJ, Preston T. Formation of short-chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200.
31. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–371.
32. McNabney SM, Henagan TM. Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity, and insulin resistance. Nutrients. 2017;9(12):1348.
33. Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.
34. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50.
35. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014;10(12):723–736.
36. Mukhopadhya I, Louis P. Gut microbiota-derived short-chain fatty acids and their role in human health and disease. Nat Rev Microbiol. 2025;23:635–651.
37. Salamone S, Nieddu M, Khalili A, Sansaro A, Bombardelli E, Rosa A, Pollastro F. Effects of quercetin and artemetin prenylation on bioavailability and bioactivity. Chem Phys Lipids. 2021;240:105137.
38. Morante-Carriel J, Živković S, Nájera H, Sellés-Marchart S, Martínez-Márquez A, Martínez-Esteso MJ. Prenylated flavonoids of the Moraceae family: a comprehensive review of their biological activities. Plants (Basel). 2024;13(9):1211.
39. Laiche MH, Barlow JW. Recent advances in the synthesis and biological applications of prenylated chalcones. Int J Mol Sci. 2025;26(20):9845.
40. Ballini A, Barile SN, De Rosa A, Bizzoca ME, Boccellino M, Scacco S. The polyphenol–microbiota axis: molecular mechanisms, metabolic pathways, and therapeutic perspectives in human health. J Pers Med. 2026;16(3):142.
41. Ozdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E. The reciprocal interactions between polyphenols and gut microbiota and effects on bioaccessibility. Nutrients. 2016;8(2):78.
42. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health. Phytochem Rev. 2004;65(10):1317-1330.
43. Smeriglio A, Barreca D, Bellocco E, Trombetta D. Proanthocyanidins and hydrolysable tannins: occurrence, dietary intake and pharmacological effects. Br. J pharmacol.2017;174(11):1244-1262.
44. Hisanaga A, Mukai R, Sakao K, Terao J, Hou DX. Anti-inflammatory effects and molecular mechanisms of 8-prenyl quercetin. Mol Nutr Food Res. 2016;60(5):1020-1032.
45. Birt DF, Boylston T, Hendrich S, Jane JL, Hollis J, Li L. Resistant starch: promise for improving human health. Adv Nutr. 2013;4(6):587–601.
46. Sun H, Ma X, Zhang S, Zhao D, Liu X. Resistant starch produces antidiabetic effects by enhancing glucose metabolism and ameliorating pancreatic dysfunction in type 2 diabetic rats. Int J Biol Macromol. 2018;110:276–285.
47. Zhang C, Dong L, Wu J, Qiao S, Xu W, Ma S. Intervention of resistant starch 3 on type 2 diabetes mellitus and its mechanism based on urine metabonomics by liquid chromatography-tandem mass spectrometry. Biomed Pharmacother. 2020;128:110350.
48. Kembabazi S, Mutambuka M, Shukri R, Anwar F, Zawawi N. Unlocking the potential of resistant starches from underutilized tropical fruits as substrates for fermentation into short-chain fatty acids. J Funct Foods. 2025;125:106630.
49. Xu T, Zhong Y, Ji S, Xiao H, Li J, Li K. RS4-type resistant starch improves type 2 diabetes mellitus in mice by interacting with Lactobacillus johnsonii. Food Front. 2025;6:268-281.
50. Chang R, Liu J, Jia F, Fu L, Xu K, Yang Y, Ma A. Hypoglycemic effect of recrystallized resistant starch on high-fat diet- and streptozotocin-induced type 2 diabetic mice via gut microbiota modulation. Int J Biol Macromol. 2024;261:129812.
51. Fu J, Liu C, Tu S, Liu H, Liu Z, He W. Dietary intervention with resistant starch-rich unripe plantain flour restores gut microbiome–metabolome axis and ameliorates type 2 diabetes in rats. Foods. 2025;14(23):3996.
52. Lopez-Pedrosa JM, Camprubi-Robles M, Guzman-Rolo G, Lopez-Gonzalez A, Garcia-Almeida JM, Sanz-Paris A, Rueda R. The vicious cycle of type 2 diabetes mellitus and skeletal muscle atrophy: clinical, biochemical, and nutritional bases. Nutrients. 2024;16(1):172.
53. Dlamini M, Khathi A. Investigating the effects of diet-induced prediabetes on skeletal muscle strength in male Sprague Dawley rats. Int J Mol Sci. 2024;25(7):4076.
54. Giron M, Thomas M, Dardevet D, Chassard C, Savary-Auzeloux I. Gut microbes and muscle function: can probiotics make our muscles stronger? J Cachexia Sarcopenia Muscle. 2022;13:1460–1476.
55. Fang J, Yan W, Sun X, Chen J. The role of exercise-induced short-chain fatty acids in the gut–muscle axis: implications for sarcopenia prevention and therapy. Front Microbiol. 2025;16:1665551.
56. Sun C, Wei Z, Xue C, Yang L. Development, application and future trends of starch-based delivery systems for nutraceuticals: a review. Carbohydr Polym. 2023;308:120675.
57. Liang X, Chen L, McClements DJ, Peng X, Xu Z, Meng M, Jin Z. Bioactive delivery systems based on starch and its derivatives: assembly and application at different structural levels. Food Chem. 2024;432:137184.
58. Aslam S, Akhtar A, Nirmal N, et al. Recent developments in starch-based delivery systems of bioactive compounds: formulations and applications. Food Eng Rev. 2022;14:271–291.
59. Qin M, Li L, Du J, Hong Y, Gu Z, Cheng L, et al. Functional factors for precision nutrition interventions in starch-based delivery systems. Crit Rev Food Sci Nutr. 2025 Sep 26:1–19.
60. Zou Z, Chen X, Gao Y, Theppawong A, Liu Y, Sangsawad P, et al. Recent insights into functional, structural, and digestibility modifications of starch through complexation with polyphenols: a review. Food Chem. 2025;482:144162.
61. Nag S, Majumder S. Starch, gallic acid, their inclusion complex and their effects in diabetes and other diseases—a review. Food Sci Nutr. 2023;11(7):1612-1621.
62. Hu Z, Xu Y, Xiong Y, Huang G. Mechanisms, functions, research methods and applications of starch–polyphenol complexes in the synergistic regulation of physiological parameters. Foods. 2025;14(18):3219.
63. Zhou JF, Xu HX, Yin ZP, Chen JG, Zhang QF. The combination effects of quercetin on starch and digestive enzymes reduce postprandial blood glucose in rats. Eur Food Res Technol.2024;250(4);1189-1199.
64. Yang P, Qiu C, Zhang N. Changes in physicochemical properties and in vitro digestibility of broken rice starch by ultrasound and quercetin dual treatment. Appl Sci. 2025;15(8):4203.
65. Wu TY, Sun NN, Chan Z, Chen CJ, Wu YC, Chau CF. Enhancement of digestion resistance and glycemic control of corn starch through conjugation with gallic acid and quercetin using the free radical grafting method. Processes. 2022;10(12):2610.
66. Ding Q, Zhang B, Zheng W, Chen X, Zhang J, Yan R. Liupao tea extract alleviates diabetes mellitus and modulates gut microbiota in rats induced by streptozotocin and high-fat, high-sugar diet. Biomed Pharmacother. 2019;118:109262.
67. Devarakonda SLS, Superdock DK, Ren J, Johnson LM. Gut microbial features and dietary fiber intake predict gut microbiota response to resistant starch supplementation. Gut Microbes. 2024;16(1):2367301.
68. Han F, Xiao Y, Lee IS. Microbial transformation of prenylquercetins by Mucor hiemalis. Molecules. 2020;25(3):528.
69. Tian S, Xue X, Wang X, Chen Z. Preparation of starch-based functional food nano-microcapsule delivery system and its controlled release characteristics. Front Nutr. 2022;9:982370.
70. Xu W, Wang Q, Yang Y, Sun S. Integrated analysis of gut microbiota, fecal and serum metabolites in type 2 diabetes mellitus with peripheral neuropathy. J Endocrinol Invest. 2025;48:2473–2488.
71. Kadibalban AS, Künstner A, Schröder T, Zauleck J. Metabolic modelling reveals increased autonomy and antagonism in type 2 diabetic gut microbiota. Mol Syst Biol. 2025;21:720–731.
72. Wang S, Wu T, Cui W, Liu M, Wu Y, Zhao C. Structure and in vitro digestibility of complex of corn starch with soy isoflavone. Food Sci Nutr. 2020;8(11):6061-6068.
73. Lee H, Son KH, Kim JH. Effects of Bombyx batryticatus extract on hyperglycemia and gut microbiota in diabetic mice induced by streptozotocin and high-fat diet. J Funct Foods. 2024;114:106495.
74. Surono IS, Wardana AA, Waspodo P, Saksono B, Verhoeven J, Venema K. Effect of functional food ingredients on gut microbiota in a rodent diabetes model. Nutr Metab (Lond). 2020;17:77